Financial Security Advisor Inc. Sells 22,920 Shares of Johnson & Johnson $JNJ

Key Points

• Financial Security Advisor Inc. cut its Johnson & Johnson stake by 51.7% in the fourth quarter, selling 22,920 shares and leaving it with 21,441 shares valued at about $4.44 million.
• Johnson & Johnson beat quarterly expectations, reporting $2.70 EPS on $24.06 billion in revenue, while also raising full-year FY2026 guidance to $11.45–$11.65 EPS.
• The company raised its quarterly dividend to $1.34 per share, and analysts remain broadly constructive with a consensus rating of Moderate Buy and an average price target of $253.04.

Financial Security Advisor Inc. cut its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 51.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,441 shares of the company's stock after selling 22,920 shares during the quarter. Johnson & Johnson makes up approximately 0.9% of Financial Security Advisor Inc.'s investment portfolio, making the stock its 24th largest holding. Financial Security Advisor Inc.'s holdings in Johnson & Johnson were worth $4,437,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in JNJ. Abich Financial Wealth Management LLC bought a new position in Johnson & Johnson in the third quarter worth about $26,000. Cresta Advisors Ltd. acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at about $26,000. DecisionPoint Financial LLC increased its holdings in shares of Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company's stock valued at $30,000 after acquiring an additional 75 shares in the last quarter. Family CFO Inc acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at about $31,000. Finally, Bay Harbor Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 49.0% during the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company's stock valued at $31,000 after acquiring an additional 49 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $226.81 on Friday. The business's 50 day moving average price is $235.13 and its 200 day moving average price is $221.79. The firm has a market cap of $545.98 billion, a P/E ratio of 26.22, a P/E/G ratio of 2.26 and a beta of 0.27. Johnson & Johnson has a 52 week low of $149.04 and a 52 week high of $251.71. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.02. The firm had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.Johnson & Johnson's revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be given a $1.34 dividend. The ex-dividend date is Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.4%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.30. Johnson & Johnson's payout ratio is currently 60.12%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the company's stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,251,310.02. This represents a 4.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 30,142 shares of company stock worth $7,360,528. Insiders own 0.16% of the company's stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Leerink Partners upgraded Johnson & Johnson (JNJ) to Outperform, which can help investor sentiment and suggests the firm sees more upside from current levels. Leerink Partners upgrades Johnson & Johnson (JNJ)
• Positive Sentiment: A new article says J&J’s story is shifting as newer drugs such as Icotyde, Inlexzo, Tecvayli and Tremfya gain attention, while a valuation update nudged fair value slightly higher. That points to continued pipeline progress as a key long-term driver. How The Story For Johnson & Johnson (JNJ) Is Shifting With New Drugs And Legal Twists
• Positive Sentiment: CAPLYTA data highlighted favorable efficacy and safety versus competing antipsychotics, reinforcing the value of J&J’s mental-health franchise and broader pipeline depth. CAPLYTA Data Highlights Johnson & Johnson Valuation And Mental Health Story
• Neutral Sentiment: MeiraGTx reported an asset purchase agreement with Johnson & Johnson for bota-vec, a transaction that appears more strategic than immediately material for earnings, but it shows J&J remains active in bolt-on pipeline deals. MeiraGTx Reports First Quarter 2026 Financial and Operational Results
• Neutral Sentiment: Recent bladder-cancer survey coverage reinforces the need for better therapies, which supports the market’s broader view that J&J’s oncology and urology pipeline could have room to grow, though the report itself does not change fundamentals immediately. Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
• Negative Sentiment: Articles note Johnson & Johnson has been down since its last earnings report, indicating some investors remain cautious despite the company’s stable fundamentals and defensive profile. Why Is Johnson & Johnson (JNJ) Down 3.5% Since Last Earnings Report?

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Scotiabank restated an "outperform" rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Citigroup upped their price objective on shares of Johnson & Johnson from $274.00 to $285.00 and gave the company a "buy" rating in a report on Tuesday, April 7th. Daiwa Securities Group upped their price objective on shares of Johnson & Johnson from $237.00 to $246.00 and gave the company an "outperform" rating in a report on Thursday, April 16th. Raymond James Financial upped their price objective on shares of Johnson & Johnson from $237.00 to $258.00 and gave the company an "outperform" rating in a report on Wednesday, April 15th. Finally, Barclays upped their price objective on shares of Johnson & Johnson from $234.00 to $255.00 and gave the company an "equal weight" rating in a report on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $253.04.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.